Marco Meglio is an editor for NeurologyLive, specializing in neurology and patient care. With a background in journalism and a passion for healthcare, Marco's work focuses on providing informative and insightful articles on the latest research, treatments, and advancements in the field of neurology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Marco Meglio's coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on neurology-related topics such as clinical trials, multiple sclerosis, Parkinson's disease, and Duchenne muscular dystrophy. His articles frequently cite data and press releases.
Given this focus, Marco may be interested in receiving pitches related to ongoing or upcoming clinical trials in the field of neurology and pharmaceuticals. Pitches that offer access to exclusive data or insights from leading experts within these areas would likely resonate well with him.
As he covers a wide range of scientific themes within healthcare and pharmaceuticals, sources should ensure that their pitches are evidence-based and provide valuable contributions to ongoing research or developments in these fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Victor Sung, MD, PhD, director of the UAB Huntington's Disease Clinic, provided perspective on some of the advances and areas of unmet on Huntington Disease Awareness Day.
By: Marco Meglio
In honor of Huntington Disease Awareness Day, held May 15, 2024, get caught up on some of the latest news in HD, with data updates and expert insights all in one place from the NeurologyLive® team.
Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.
By: Marco Meglio
The study found that Black, Asian, and Hispanic individuals have 7- to 4-fold higher incidence of anti-NMDAR encephalitis, a rare epileptic condition, than White individuals.
By: Marco Meglio
Labeling updates underscore the importance of using compatible autoinjectors with specific glatiramer acetate injection products to prevent medication errors.
By: Marco Meglio
Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Michael Weiss, CEO of TG Therapeutics. [LISTEN TIME: 19 minutes]
By: Marco Meglio
Voyager expects insights from the phase 1 study to inform a subsequent phase 1b trial and anticipates tau PET imaging data in 2026.
By: Marco Meglio
ION541, an antisense oligonucleotide, failed to demonstrate impact on outcomes of function, breathing, and strength, in addition to no impact on neurofilament light.
Sean Pittock, MD, director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology detailed interim data from the open-label extension of the pivotal CHAMPION-NMOSD trial, the study that led to ravulizumab's approval.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Huntington disease.
(833) 317-6278 
